Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(0.70)
# 3,686
Out of 4,712 analysts
93
Total ratings
22.35%
Success rate
-32.24%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Initiates: Buy | $30 | $9.75 | +207.69% | 1 | Dec 16, 2024 | |
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $28 | $7.50 | +273.33% | 7 | Dec 12, 2024 | |
| IRD Opus Genetics | Reiterates: Buy | $8 | $1.04 | +669.23% | 1 | Dec 12, 2024 | |
| IMUX Immunic | Initiates: Buy | $10 | $1.05 | +852.38% | 1 | Nov 25, 2024 | |
| ADVM Adverum Biotechnologies | Reiterates: Buy | $30 | $4.74 | +532.91% | 4 | Nov 19, 2024 | |
| EYEN Eyenovia | Downgrades: Neutral | $12 → $2 | $0.09 | +2,236.45% | 14 | Nov 18, 2024 | |
| KOD Kodiak Sciences | Reiterates: Neutral | $3 | $9.87 | -69.60% | 3 | Nov 15, 2024 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $7 | $5.26 | +33.08% | 3 | Nov 15, 2024 | |
| FDMT 4D Molecular Therapeutics | Reiterates: Buy | $36 | $5.81 | +519.62% | 15 | Nov 14, 2024 | |
| FBLG FibroBiologics | Reiterates: Buy | $12 | $2.31 | +419.48% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.38 | +1,213.03% | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $12.80 | +134.38% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $31.50 | +20.63% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $3.63 | +230.58% | 4 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $0.17 | +1,060.77% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.87 | +6.95% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.76 | +110.30% | 10 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.00 | +900.00% | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $221.24 | -87.34% | 1 | Aug 22, 2023 |
Zenas BioPharma
Dec 16, 2024
Initiates: Buy
Price Target: $30
Current: $9.75
Upside: +207.69%
Phathom Pharmaceuticals
Dec 12, 2024
Reiterates: Buy
Price Target: $28
Current: $7.50
Upside: +273.33%
Opus Genetics
Dec 12, 2024
Reiterates: Buy
Price Target: $8
Current: $1.04
Upside: +669.23%
Immunic
Nov 25, 2024
Initiates: Buy
Price Target: $10
Current: $1.05
Upside: +852.38%
Adverum Biotechnologies
Nov 19, 2024
Reiterates: Buy
Price Target: $30
Current: $4.74
Upside: +532.91%
Eyenovia
Nov 18, 2024
Downgrades: Neutral
Price Target: $12 → $2
Current: $0.09
Upside: +2,236.45%
Kodiak Sciences
Nov 15, 2024
Reiterates: Neutral
Price Target: $3
Current: $9.87
Upside: -69.60%
DiaMedica Therapeutics
Nov 15, 2024
Reiterates: Buy
Price Target: $7
Current: $5.26
Upside: +33.08%
4D Molecular Therapeutics
Nov 14, 2024
Reiterates: Buy
Price Target: $36
Current: $5.81
Upside: +519.62%
FibroBiologics
Nov 13, 2024
Reiterates: Buy
Price Target: $12
Current: $2.31
Upside: +419.48%
Nov 13, 2024
Reiterates: Buy
Price Target: $5
Current: $0.38
Upside: +1,213.03%
Nov 12, 2024
Reiterates: Buy
Price Target: $30
Current: $12.80
Upside: +134.38%
Nov 7, 2024
Reiterates: Buy
Price Target: $38
Current: $31.50
Upside: +20.63%
Sep 3, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $3.63
Upside: +230.58%
Aug 15, 2024
Reiterates: Neutral
Price Target: $2
Current: $0.17
Upside: +1,060.77%
Aug 12, 2024
Reiterates: Neutral
Price Target: $2
Current: $1.87
Upside: +6.95%
Aug 9, 2024
Reiterates: Buy
Price Target: $10
Current: $4.76
Upside: +110.30%
Nov 14, 2023
Reiterates: Buy
Price Target: $10
Current: $1.00
Upside: +900.00%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $221.24
Upside: -87.34%